New study compares caldolor® (ibuprofen injection) to ketorolac

–        real world study compared over 150,000 adult & pediatric patients – –        caldolor associated with fewer adverse drug reactions – –        caldolor also improved healthcare utilization – nashville, tenn. , nov. 5, 2024 /prnewswire/ -- specialty pharmaceutical company cumberland pharmaceuticals (nasdaq: cpix) today announced the publication of new real-world outcomes research demonstrating the safety and healthcare resource advantages of its caldolor (ibuprofen) injection over ketorolac in both adult and pediatric populations.
CPIX Ratings Summary
CPIX Quant Ranking